Holmium Laser Enucleation of the Prostate — size-independent removal of large adenomas along the surgical capsule plane
Benign prostatic hyperplasia (BPH) causing bladder outlet obstruction affects the majority of men by their 70s. While transurethral resection of the prostate (TURP) remains a workhorse for glands under ~80mL, very large glands historically forced a choice between prolonged, higher-risk TURP or open simple prostatectomy with its incision, longer stay, and greater blood loss. HoLEP was developed specifically to remove this size ceiling entirely.
Standard monopolar or bipolar TURP resects adenoma tissue in small chips using an electrified loop. Resection time scales roughly linearly with gland volume, and prolonged resection increases irrigation fluid absorption, bleeding, and — for monopolar TURP — risk of TUR syndrome (dilutional hyponatremia from hypotonic irrigant absorption). Most guidelines cap monopolar TURP at glands under ~60–80mL and recommend alternative techniques above that size.
For decades, the accepted alternative for glands >80–100g was open simple prostatectomy (transvesical Freyer or retropubic Millin approach): effective and durable, but requiring an abdominal incision, longer hospitalization, and substantially higher blood loss and transfusion risk.
HoLEP breaks this size dependency because laser enucleation follows an anatomical plane rather than resecting tissue piecemeal — the technique is essentially an endoscopic reproduction of open enucleation, so operative time scales with surgeon efficiency and gland size rather than an inherent technology limit.
Multiple randomized trials and the AUA/EAU guidelines now recognize HoLEP as size-independent — a single technique appropriate for a 30 mL gland and a 300+ g gland, unlike TURP (size-limited) or open prostatectomy (traditionally reserved for the largest glands only).
Because the Ho:YAG laser coagulates vessels up to roughly 2–4mm as it cuts, HoLEP produces a comparatively dry surgical field even in patients who cannot safely stop anticoagulant or antiplatelet therapy — a population that is often denied TURP or open surgery due to bleeding risk.
Published series report HoLEP performed safely on patients continuing warfarin, direct oral anticoagulants (DOACs), or dual antiplatelet therapy, with transfusion rates that remain under 1% even in this higher-risk subgroup — a substantial advantage for older, comorbid men who represent a growing share of BPH surgical candidates.
Other favorable candidates include patients with large median lobe intravesical protrusion, urinary retention with a large trabeculated bladder, and those who specifically wish to avoid an abdominal incision and its associated recovery time.
Work-up mirrors other BPH surgery pathways with attention to gland size and anticoagulation status:
• Transrectal or abdominal ultrasound to estimate gland volume (mL), which approximates resected tissue mass in grams • PSA and, where indicated, prostate biopsy to exclude malignancy — incidental prostate cancer is identified in a meaningful minority of enucleated specimens since the entire transition zone is sent for pathology (an advantage over TURP chips) • Urinalysis/culture to exclude active infection • Review of anticoagulant/antiplatelet regimen with the prescribing physician — many patients can continue therapy through HoLEP given its hemostatic profile • Discussion of ejaculatory function: retrograde ejaculation occurs in a large majority of sexually active men after HoLEP, similar to TURP, since the technique removes obstructing tissue up to the verumontanum
The defining technical concept of HoLEP is the surgical capsule — the compressed, largely avascular layer of true prostatic tissue that separates the hyperplastic adenoma from the prostatic fossa. This is the exact same plane surgeons have used for over a century in open simple prostatectomy; HoLEP simply develops it endoscopically with a laser instead of a finger.
The holmium:yttrium-aluminum-garnet (Ho:YAG) laser emits pulsed infrared light at 2,100 nm, a wavelength that is almost perfectly absorbed by water — the dominant constituent of soft tissue. This produces a very shallow penetration depth (roughly 0.3–0.4 mm), meaning the laser vaporizes and cuts tissue essentially at the fiber tip without significant deep thermal spread.
The same pulsed energy that vaporizes tissue also coagulates small-to-medium vessels in the beam path (vessels up to ~2–4mm), giving Ho:YAG its trademark "cut and seal" property. This is what allows enucleation of a large vascular organ with markedly less bleeding than electrosurgical resection.
Newer pulse-modulation technology (e.g. MOSES) reshapes the laser pulse to reduce backscatter through irrigant fluid and bubbles, improving cutting efficiency and further reducing tissue retropulsion, allowing surgeons to work at higher net power with better hemostasis.
Because Ho:YAG energy is absorbed almost entirely within half a millimeter of tissue, the surgeon can trace the capsule plane with millimeter precision — cutting the vascular adenoma pedicles while leaving the thin true capsule intact, the same margin a surgeon's finger seeks blindly during open enucleation.
The prostate's transition zone, where BPH nodules arise, expands and compresses the surrounding peripheral and central zone tissue into a thin, fibrous rind — the "surgical" or "false" capsule. This layer is distinct from the true anatomical prostatic capsule and represents the natural cleavage plane between benign adenoma and the compressed residual gland.
Enucleation begins with two longitudinal incisions near the bladder neck (typically at the 5 and 7 o'clock positions) carried down to the surgical capsule, identified by its characteristic circular fibers and paler, glistening appearance compared to the more vascular, nodular adenoma.
Once the plane is entered, a combination of laser incision and blunt pushing with the scope sheath develops the plane circumferentially — analogous to peeling an orange, where the laser divides fibrous attachments and vascular pedicles while the endoscope itself provides gentle blunt dissection force.
Bleeding during HoLEP arises mainly from two structures: the arterial pedicles at the 5 and 7 o'clock positions near the bladder neck (branches of the inferior vesical artery) and the capsular venous plexus at the apex. Both are anticipated and pre-coagulated with defocused laser energy before full transection whenever possible.
Because the laser is both the cutting and the coagulating instrument, hemostasis is continuous throughout dissection rather than a separate step performed after resection (as in TURP, where diathermy fulguration is applied only once bleeding is already visible in a chip-filled field).
This continuous coagulation is the principal mechanistic reason HoLEP produces measured hemoglobin drops roughly half those of TURP despite treating, on average, much larger glands.
With the capsule plane identified, the surgeon systematically frees each anatomical lobe of the adenoma and displaces it into the bladder, where it floats freely as a large intact (or near-intact) specimen awaiting morcellation. The trilobar technique — median lobe first, then the two lateral lobes — is the most widely taught sequence.
The median lobe, when present, is enucleated first because it can obstruct the working view of the bladder neck. Two incisions are made from the bladder neck converging toward the apex just proximal to the verumontanum, and the plane between adenoma and capsule is developed until the median lobe is attached only by a thin mucosal bridge at the bladder neck, which is then divided, releasing it to float freely in the bladder.
Each lateral lobe is then approached in turn: the surgeon incises along the previously developed median groove and along the 12 o'clock (or paramedian) position, sweeping circumferentially around the capsule while the endoscope sheath is used to bluntly push the lobe cephalad, "unrolling" it away from the capsule much as a surgeon's finger would during an open Millin prostatectomy.
The most delicate portion of the dissection is the apex, immediately proximal to the external urinary sphincter and verumontanum. Careful sharp laser dissection here — rather than blunt pushing — protects the sphincter mechanism and is central to preserving post-operative continence; apical over-resection is the main technical driver of transient or, rarely, persistent stress incontinence after HoLEP.
Once circumferential dissection is complete, each lobe is tethered to the bladder neck by only a narrow mucosal strip, which is divided with the laser, releasing the entire lobe to float as a large free specimen in the bladder for later morcellation.
A key safety principle: at the end of enucleation, all three lobes are detached and pushed into the bladder before any morcellation begins — this avoids repeatedly re-introducing a morcellator into a partially dissected fossa and keeps the bleeding capsule under continuous visual control until the fossa is otherwise complete.
While the trilobar (three-lobe) technique described above is the classic teaching approach, experienced surgeons have described variations including two-lobe techniques (treating both lateral lobes with the median lobe as part of one of them) and early apical release techniques that divide the apical mucosa first to shorten operative time. All variants share the same underlying principle: complete circumferential separation of adenoma from the surgical capsule before morcellation, achieving anatomic completeness similar to an open simple prostatectomy specimen.
Enucleation frees the adenoma from the capsule, but the large intact lobes floating in the bladder are far too large to remove through the urethra intact. A mechanical morcellator — a specialized nephroscope attachment with oscillating or rotating cutting blades and continuous suction — grinds the tissue into aspirable fragments under direct endoscopic vision.
The morcellator is passed through a dedicated nephroscope (rather than the resectoscope used for enucleation) under continuous irrigation with a clear bladder full of fluid to keep the free-floating tissue lobes suspended and away from the bladder wall. Its working end has two blades — one fixed, one oscillating or rotating at high speed — that grasp tissue drawn in by active suction and shear it into small fragments, which are aspirated through the device into a collection trap for pathological analysis.
The cardinal safety rule of morcellation is "never activate suction/cutting unless tissue is clearly visualized filling the endoscopic field" — inadvertent grasping of bladder mucosa is the principal serious complication of this step and is avoided by maintaining a full bladder (distending it away from the morcellator tip) and only morcellating tissue actively pulled into direct view.
Morcellation efficiency depends on tissue consistency (softer glandular tissue morcellates faster than fibrous or previously-treated tissue), bladder distension, and device generation — modern morcellators achieve roughly 4–8 grams per minute, so a 100–150g specimen typically requires 15–30 minutes of morcellation time, a substantial fraction of total operative time in very large glands.
Because essentially the entire enucleated adenoma is aspirated and sent to pathology (unlike TURP, where only representative resected chips are sampled), HoLEP offers more complete pathological assessment of the prostate — clinically significant, since incidental prostate cancer is detected in a meaningful percentage of specimens, more often than with TURP sampling of the same gland.
Early morcellators used a single oscillating blade design; later generations introduced dual-action rotating/reciprocating blades and improved suction dynamics to reduce morcellation time and the risk of tissue "chasing" (fragments evading the blades). Some surgeons now favor early apical release combined with more efficient morcellator generations specifically to shorten this historically time-consuming step, which — together with laser enucleation speed — is one of the two components most responsible for total case duration and thus a major focus of the technique's learning curve.
Two decades of comparative trials now show HoLEP delivers durable, TURP-equivalent-or-better functional relief of bladder outlet obstruction, with markedly lower blood loss and faster catheter removal than either TURP or open prostatectomy — at the well-documented cost of a long and technically demanding learning curve that has slowed its adoption relative to its clinical advantages.
Randomized trials and meta-analyses comparing HoLEP against TURP and open simple prostatectomy consistently show:
• Hemoglobin drop: ~0.5–1.0 g/dL after HoLEP vs. ~1.5–2.5 g/dL after TURP and ~2–4 g/dL after open prostatectomy, despite HoLEP series often treating larger glands • Catheterization time: often removed the morning after surgery (postop day 1) for HoLEP, vs. 1–3 days for TURP and 3–5+ days for open prostatectomy • Hospital stay: typically 1–2 days for HoLEP, similar or slightly shorter than TURP, and substantially shorter than the 3–5+ days typical of open surgery • Irrigation fluid absorption / TUR syndrome: essentially eliminated with HoLEP's saline irrigation, versus a real (if now uncommon with bipolar) risk with monopolar TURP • Catheterized/retreatment for clot retention: lower with HoLEP given superior intraoperative hemostasis
A frequently cited comparative statistic: HoLEP achieves roughly half the hemoglobin drop of TURP while frequently treating glands two to three times larger — the combination of size-independence and superior hemostasis is what has driven its adoption as the preferred technique for very large prostates at high-volume centers.
Because HoLEP removes essentially the entire adenoma down to the surgical capsule — anatomically equivalent to an open simple prostatectomy specimen — its durability at 5–10 years of follow-up closely tracks open prostatectomy rather than TURP. Reoperation rates for recurrent obstruction (regrowth of residual adenoma) are low, in the range of 1–3% at long-term follow-up, comparable to open surgery and generally lower than large-gland TURP, where more residual tissue may be left behind.
Uroflowmetry (Qmax) improvements and symptom score (IPSS) reductions are durable and comparable to, or better than, TURP across multiple randomized trials with 5+ years of follow-up, with no significant late deterioration attributable to the laser technique itself.
Despite its clinical advantages, HoLEP has a well-documented and comparatively steep learning curve. Published estimates suggest approximately 20 mentored cases (with an experienced proctor) or up to 50 or more unmentored cases are needed before a surgeon's operative times, enucleation efficiency, and complication rates plateau at expert benchmarks.
The two skills that take longest to master are: (1) correctly and confidently identifying the surgical capsule plane in gland regions with variable fibrosis or prior instrumentation, and (2) apical dissection technique that protects the external sphincter without leaving excess obstructing tissue. Structured training curricula, simulation/dry-lab modules, and mentored proctorship programs have been shown to meaningfully shorten this curve and are now widely recommended before independent HoLEP practice.
This learning curve — more than any patient-outcome disadvantage — remains the main reason HoLEP, despite superior evidence in many domains, has not yet supplanted TURP as the most commonly performed BPH surgery worldwide.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| HoLEP | |||
| TURP (mono/bipolar) | |||
| Open Simple Prostatectomy |